[go: up one dir, main page]

WO2009041789A3 - Nouveau dérivé 3-chloro-5-substitué-quinoxaline-2-amine et sel pharmaceutiquement acceptable, procédé de préparation, agent thérapeutique utilisé contre une maladie inflammatoire induite par une activité spc, contenant le dérivé 3-chloro-5-substitué-quinoxaline-2-amine comme principe actif - Google Patents

Nouveau dérivé 3-chloro-5-substitué-quinoxaline-2-amine et sel pharmaceutiquement acceptable, procédé de préparation, agent thérapeutique utilisé contre une maladie inflammatoire induite par une activité spc, contenant le dérivé 3-chloro-5-substitué-quinoxaline-2-amine comme principe actif Download PDF

Info

Publication number
WO2009041789A3
WO2009041789A3 PCT/KR2008/005725 KR2008005725W WO2009041789A3 WO 2009041789 A3 WO2009041789 A3 WO 2009041789A3 KR 2008005725 W KR2008005725 W KR 2008005725W WO 2009041789 A3 WO2009041789 A3 WO 2009041789A3
Authority
WO
WIPO (PCT)
Prior art keywords
chloro
quinoxaline
substituted
amine derivatives
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/KR2008/005725
Other languages
English (en)
Other versions
WO2009041789A2 (fr
Inventor
Young-Dae Gong
Heeyeong Cho
Moon-Kook Jeon
Taeho Lee
Gildon Choi
Jae-Yang Kong
Woo-Kyu Park
Soon-Hee Hwang
Jung Ju Kim
Chang-Hoon Lee
Jaeyoung Ko
Minsoo Noh
Eun Sil Han
Hyuk Kim
Jun-Won Yun
Joo Hyun Moh
Do Hoon Kim
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Korea Research Institute of Chemical Technology KRICT
Amorepacific Corp
Original Assignee
Korea Research Institute of Chemical Technology KRICT
Amorepacific Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Korea Research Institute of Chemical Technology KRICT, Amorepacific Corp filed Critical Korea Research Institute of Chemical Technology KRICT
Publication of WO2009041789A2 publication Critical patent/WO2009041789A2/fr
Publication of WO2009041789A3 publication Critical patent/WO2009041789A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Rheumatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne un dérivé 3-chloro-5-substitué-quinoxaline-2-amine représenté par la formule chimique 1 suivante, un sel pharmaceutiquement acceptable dudit dérivé, son procédé de préparation et son utilisation comme principe actif dans un agent thérapeutique utilisé contre une maladie inflammatoire induite par la sphingosylphosphorylcholine (SPC). Le dérivé 3-chloro-5-substitué-quinoxaline-2-amine de l'invention présente de manière confirmée une activité inhibitrice supérieure contre le récepteur de la SPC dans une expérience animale dans laquelle sont utilisées des cellules endothéliales humaines et des souris. Une composition pharmaceutique pour le traitement d'une maladie inflammatoire, contenant ledit dérivé 3-chloro-5-substitué-quinoxaline-2-amine ou un sel pharmaceutiquement acceptable de celui-ci comme principe actif, peut ainsi être utilisée pour traiter l'inflammation, les démangeaisons ou les infections cutanées associées à une dermatite atopique ou une autre maladie induite par l'activité du récepteur de la SPC.
PCT/KR2008/005725 2007-09-27 2008-09-26 Nouveau dérivé 3-chloro-5-substitué-quinoxaline-2-amine et sel pharmaceutiquement acceptable, procédé de préparation, agent thérapeutique utilisé contre une maladie inflammatoire induite par une activité spc, contenant le dérivé 3-chloro-5-substitué-quinoxaline-2-amine comme principe actif Ceased WO2009041789A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020070097554A KR100916716B1 (ko) 2007-09-27 2007-09-27 3-클로로-5-치환-퀴녹살린-2-아민 유도체 및 약제학적으로허용 가능한 그의 염, 그의 제조방법 및 그를 유효성분으로함유하는 ｓｐｃ 수용체 활성으로 유발되는 염증관련 질환치료제
KR10-2007-0097554 2007-09-27

Publications (2)

Publication Number Publication Date
WO2009041789A2 WO2009041789A2 (fr) 2009-04-02
WO2009041789A3 true WO2009041789A3 (fr) 2009-05-14

Family

ID=40512033

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2008/005725 Ceased WO2009041789A2 (fr) 2007-09-27 2008-09-26 Nouveau dérivé 3-chloro-5-substitué-quinoxaline-2-amine et sel pharmaceutiquement acceptable, procédé de préparation, agent thérapeutique utilisé contre une maladie inflammatoire induite par une activité spc, contenant le dérivé 3-chloro-5-substitué-quinoxaline-2-amine comme principe actif

Country Status (2)

Country Link
KR (1) KR100916716B1 (fr)
WO (1) WO2009041789A2 (fr)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004054584A1 (fr) * 2002-12-13 2004-07-01 Merck & Co., Inc. Nouveaux derives de quinoxalinone constituant des antagonistes b1 de la bradykinine
US20050020590A1 (en) * 2003-07-25 2005-01-27 Hengyuan Lang P-38 kinase inhibitors
US20050020600A1 (en) * 2003-07-23 2005-01-27 Scherer Warren J. Methods of treating cutaneous flushing using selective alpha-2-adrenergic receptor agonists

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003062234A1 (fr) * 2002-01-23 2003-07-31 Yamanouchi Pharmaceutical Co., Ltd. Composes de quinoxaline

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004054584A1 (fr) * 2002-12-13 2004-07-01 Merck & Co., Inc. Nouveaux derives de quinoxalinone constituant des antagonistes b1 de la bradykinine
US20050020600A1 (en) * 2003-07-23 2005-01-27 Scherer Warren J. Methods of treating cutaneous flushing using selective alpha-2-adrenergic receptor agonists
US20050020590A1 (en) * 2003-07-25 2005-01-27 Hengyuan Lang P-38 kinase inhibitors

Also Published As

Publication number Publication date
KR20090032373A (ko) 2009-04-01
WO2009041789A2 (fr) 2009-04-02
KR100916716B1 (ko) 2009-09-10

Similar Documents

Publication Publication Date Title
TW200716648A (en) Heterocycles as nicotinic acid receptor agonists for the treatment of dyslipidemia
WO2010098600A3 (fr) Dérivés d'azole substitués, composition pharmaceutique contenant les dérivés et procédé de traitement de la maladie de parkinson à l'aide de ceux-ci
WO2009106980A3 (fr) Dérivés d'indazole
PH12013501594A1 (en) Substituted indazole derivatives active as kinase inhibitors
TW200738729A (en) Heterocycles as nicotinic acid receptor agonists for the treatment of dyslipidemia
NO20073719L (no) Kjemiske forbindelser
NO20080408L (no) Azaindazolforbindelser og anvendelse derav
WO2011027249A3 (fr) Dérivés de benzimidazole
NO20084872L (no) 2-pyridonderivater for behandling av sykdom eller tilstander der inhibering av neutrofil elastaseaktivitet er gunstig
ATE557015T1 (de) 3,4-diarylpyrazole als proteinkinaseinhibitoren
NO20071246L (no) Kinazolinonderivater og deres anvendelse som B-RAF-inhibitorer.
MX2009006401A (es) Derivados de indazol como inhibidores de cinasa para el tratamiento del cancer.
NO20070199L (no) Substituerte kinazoloner som anti-kreftmidler
NO20084496L (no) Pyridyl- og pyrimidinylsubstituerte pyrrol-, tiofen- og furanderivater som kinaseinhibitorer
WO2009071480A3 (fr) Dérivés de dihydroptéridin-6-one substitués, procédé de préparation desdits dérivés et leur utilisation en tant qu'inhibiteurs de kinase
MEP23808A (en) Pyridine[3,4-b]pyrazinones
NO20084202L (no) 4-anilinoquinolin-3-carboksamider som CSF-1R kinase inhibitorer
TW200833693A (en) Substituted pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors
UA105781C2 (uk) Низькомолекулярне полісульфатоване похідне гіалуронової кислоти і лікарський засіб, який його містить
NO20084853L (no) Forbindelser som er agonister av muscarinreseptorer og som kan vaere effektive i behandling av smerte, Alzheimers sykdom og/eller schizofreni
WO2007071963A3 (fr) Composes chimiques
NO20083058L (no) Cykloheksylsulfonamidderivater med H3 reseptor aktivitet
MX368157B (es) Formulaciones de sal de meglumina del acido 1-(5,6-dicloro-1h-benz o[d]imidazol-2-il)-1h-pirazol-4-carboxilico.
MX2010009462A (es) Derivados de indazol.
ATE496918T1 (de) Als a2b-adenosinrezeptorantagonisten geeignete 5- phenyl-6-pyridin-4-yl-1,3-dihydro-2h-imidazoä4, - büpyridin-2-onderivate

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08832998

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08832998

Country of ref document: EP

Kind code of ref document: A2